[微笑]_老虎社区_美港股上老虎

kiwicub
2021-11-10

[微笑]

Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付12亿美元购买160万个疗程的默克COVID-19药物</blockquote>

Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japane

Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付12亿美元购买160万个疗程的默克COVID-19药物</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":847708663,"tweetId":"847708663","gmtCreate":1636551884468,"gmtModify":1636551884553,"author":{"id":4087173810832020,"idStr":"4087173810832020","authorId":4087173810832020,"authorIdStr":"4087173810832020","name":"kiwicub","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑]&nbsp;</span></p></body></html>","text":"[微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/847708663","repostId":1152344100,"repostType":4,"repost":{"id":"1152344100","kind":"news","pubTimestamp":1636550697,"share":"https://www.laohu8.com/m/news/1152344100?lang=zh_CN&edition=full","pubTime":"2021-11-10 21:24","market":"us","language":"en","title":"Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付12亿美元购买160万个疗程的默克COVID-19药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1152344100","media":"Reuters","summary":"Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japane","content":"<p>Nov 10 (Reuters) - Merck &amp; Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.</p><p><blockquote>路透11月10日-默克公司及其合作伙伴Ridgeback Biotherapeutics周三表示，日本政府将为其160万个疗程的COVID-19抗病毒药物molnupiravir支付约12亿美元。</blockquote></p><p> Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>各国纷纷签署购买molnupiravir的协议，因为上个月的数据显示，如果在疾病早期服用该药物，对于那些最有可能患严重COVID-19的人来说，死亡或住院的几率可以减半。</blockquote></p><p> Merck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.</p><p><blockquote>默沙东预计到2021年底将生产1000万个疗程，2022年至少生产2000万个疗程。</blockquote></p><p> If it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.</p><p><blockquote>如果获得授权，molnupiravir将成为新冠肺炎的第一种口服抗病毒药物。</blockquote></p><p> On Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.</p><p><blockquote>周二，美国政府表示将再购买价值10亿美元的molnupiravir。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付12亿美元购买160万个疗程的默克COVID-19药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill<blockquote>日本将支付12亿美元购买160万个疗程的默克COVID-19药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-10 21:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 10 (Reuters) - Merck &amp; Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.</p><p><blockquote>路透11月10日-默克公司及其合作伙伴Ridgeback Biotherapeutics周三表示，日本政府将为其160万个疗程的COVID-19抗病毒药物molnupiravir支付约12亿美元。</blockquote></p><p> Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>各国纷纷签署购买molnupiravir的协议，因为上个月的数据显示，如果在疾病早期服用该药物，对于那些最有可能患严重COVID-19的人来说，死亡或住院的几率可以减半。</blockquote></p><p> Merck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.</p><p><blockquote>默沙东预计到2021年底将生产1000万个疗程，2022年至少生产2000万个疗程。</blockquote></p><p> If it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.</p><p><blockquote>如果获得授权，molnupiravir将成为新冠肺炎的第一种口服抗病毒药物。</blockquote></p><p> On Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.</p><p><blockquote>周二，美国政府表示将再购买价值10亿美元的molnupiravir。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152344100","content_text":"Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.\nCountries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.\nIf it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.\nOn Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":1917,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}